A great DOUBLE-PLAY in a down market: HMSC at $4 and its sister SKML at .78 have just started to rock, and are ready to ROLL next week on POSITIVE NEWS. A shorts worst nightmare is coming- HUGE NEWS and POSITIVE INSTITUTIONAL EXPOSURE next week. HMSC the manufacturer and SKML the licensor will be ROCKIN THE CASBAH!
Similar to VVUS, we've got 500,000 shorts holed up in a bunker
here at HMSC with chaff lighting up the night sky. With buys outpacing sells by 3-1 lately in a 500 share market this week, the smart shorts
have already started to run for cover. Theres no big exit doors here
like VVUS, because no options are traded. No Reg S's and warrants
will help the shorts either- THEY'RE TRAPPED ON ANY BIG NEWS, and
a BIG RUN WILL ENSUE! INCOMMMMMMMINGGGGG.........
Trading just a few thousand a day, Ike and his SHORTBUSTERS have
targeted this DOUBLE PLAY of HMSC and SKML and have been
accumulating HMSC since $2.25 last week and SKML since .62 in preparation for next weeks fireworks:
1. Big April-May sales
2. Positive clinical results
3. Smith Barney conference June 25-26
Shorts that dont cover by Monday will be burned badly! HMSC and SKML
are gonna BLAST OFF!
From Yahoo:
"HMSC has been a traders dream stock. It currently looks poised to continue its ascent to a more respectable trading range. Any positive news in the near term will drive HMSC's price up quickly. I'd wager that some institutional buying (wouldn't be surprised if it was Smith Barney) is taking place in anticipation of near term announcements and next week's Smith Barney healthcare conference. I expect HMSC to report (any day now) sales for April (which will probably exceed the first three months combined, based on March unit volume vs. Jan. & Feb.) Other potential drivers include announcement of clinicals & a permanent CEO. I am in again at an average cost in the low $3's.
Results from clinicals will be reported in June (expect confirmation that Breast Alert works. These clinicals are being done to have updated data to presnet to medical community. Earlier clinicals confirmed Breast Alert's sensitivity toward breast cancer
detection. This is the whole reason we became investors in the first place.)
April sales will be reported in teh near future and reflect higher unit sales than prior months (possibly all months combined).
Company has plenty of cash to make it through end of year.
Company could be very attractive to a large medical products company even if it can't make it on its own, with its limited resources.
HMSC should begin redirecting its strategy with its interim CEO and soon to be found permanent CEO, plus input from various large institutional investors, with significant experience with start-up companies.
This company isn't going quietly into the night.
I've stock has been beaten down by day traders as almost all of the original investors have not sold. I am aware of a few that have unloaded a small percentage, but this occurs all the time in the IPO world.
This is what we can look forward to in the coming weeks:
HMSC speaking at Smith Barney healthcare conference later this month.
Results from clinical trials.
April and perhaps May unit sales data & number of docs using product.
A new public image with Brounstein gone and a female CEO leading a company, whose product is aimed at saving women's lives.
Company can certainly continue into 1999 without any additional cash infusion. With the substantial short position as a % of the float, any positive news drives the stock up."
John Sasen, PSS's President has stated his belief that BreastAlert has the potential to be the product of the decade. Re-orders would provide a nice income stream for reps. once sales ramp up as well. In case you did not know, BreastAlert has been given priority attention within PSS. While time will tell, stock looks attractive at current
levels. Any positive news will create strong upward momentum. My sense is that some of the shorts are beginning to cover in anticipation of:
upcoming Smith Barney conference where HMSC will be presenting, update on monthly unit sales, results from recently updated clinical trials and anticipated appointment of permanent CEO.
Clinicals were recently completed using the BreastAlert. Based on positive reults from earlier clinical trials using the core technology, we have every reason to believe the results from these trials will validate BreastAlert's efficicacy. There is a huge market
even if only a fraction of OBGYN's use this product. As a long term holder, I recently picked up some more shares at these levels." |
